Reumatologia Clinica最新文献

{"title":"Comment on: “Safety of biologic and synthetic targeted therapies in patients with immune-mediated diseases: Data from the BIOBADAGUAY registry”","authors":"Sarah Aijaz , Raveen Muzaffer","doi":"10.1016/j.reuma.2025.501871","DOIUrl":"10.1016/j.reuma.2025.501871","url":null,"abstract":"","PeriodicalId":47115,"journal":{"name":"Reumatologia Clinica","volume":"21 4","pages":"Article 501871"},"PeriodicalIF":1.2,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143936872","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Novel imaging findings of masticatory muscle edema in dermatomyositis associated with ovarian cancer: A case report","authors":"Leonardo F. Freitas , Márcio Luís Duarte , Kevin J. Abrams","doi":"10.1016/j.reuma.2025.501857","DOIUrl":"10.1016/j.reuma.2025.501857","url":null,"abstract":"","PeriodicalId":47115,"journal":{"name":"Reumatologia Clinica","volume":"21 4","pages":"Article 501857"},"PeriodicalIF":1.2,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143936873","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Raoul Dufy: color y resiliencia en la lucha contra la artritis reumatoide","authors":"Fernando Canillas,&nbsp;Marta Canillas","doi":"10.1016/j.reuma.2025.501847","DOIUrl":"10.1016/j.reuma.2025.501847","url":null,"abstract":"<div><div>Raoul Dufy was born in 1877 in the city of Le Havre, France. He showed an early interest in painting and attended the École des Beaux Arts in Paris, where he was influenced by Impressionism and later by Fauvism and Cubism. He achieved a style of his own, marked by colour. His paintings depicted modern life, often with bright colours and energetic scenes of urban and social life. In 1935, he developed severe rheumatoid arthritis, which affected his hands and joints. Despite this, he continued to create art until his death. He underwent numerous medical treatments of the time. In 1950, he was invited to the United States to participate in initial ACTH and cortisone therapies and achieved a significant improvement. He returned to France, but died in 1953 at the age of 76 from an intestinal haemorrhage. His artistic legacy and his strength to face this disease are an inspiration for the future.</div></div>","PeriodicalId":47115,"journal":{"name":"Reumatologia Clinica","volume":"21 4","pages":"Article 501847"},"PeriodicalIF":1.2,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143936779","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Evaluation of kinesiophobia and physical activity levels in patients with fibromyalgia syndrome and chronic neck pain","authors":"Melek Aykut Selçuk ,&nbsp;Gülseren Demir Karakılıç ,&nbsp;Esra Mert ,&nbsp;Burcu Duyur Çakıt","doi":"10.1016/j.reuma.2025.501849","DOIUrl":"10.1016/j.reuma.2025.501849","url":null,"abstract":"<div><h3>Introduction</h3><div>We aimed to evaluate pain, kinesiophobia, physical activity, depression, disease severity and fatigue in patients with Fibromyalgia syndrome (FMS) and chronic neck pain (CNP) and healthy controls.</div></div><div><h3>Material and methods</h3><div>Fifty-two patients with FMS (group 1), 52 patients with CNP (group 2) and 52 healthy controls (group 3) were included in the study. Visual Analog Scale (VAS) was used to evaluate pain intensity and fatigue, Tampa Scale of Kinesiophobia (TSK) for kinesiophobia, Beck Depression Inventory (BDI) for depression, International Physical Activity Questionnaire (IPAQ) Short Form for physical activity level, Revised Fibromyalgia Impact Questionnaire (rFIQ) for functional status in FMS, and Neck Pain Disability Index (NPDI) for neck pain-related disability in patients with CNP.</div></div><div><h3>Results</h3><div>The mean age was similar in all three groups (42.96) and the ratio of female was higher in all three groups (94.2%, 90%, 88.6%). High level kinesiophobia was present in 86.6% of patients in group 1, 63.3% of patients in group 2 and 23.4% of participants in group 3 and statistically, kinesiophobia was more common in groups 1 than in groups 2 and 3 and in group 2 than in group 3. The rate of depression was 80%, 50% and 16% in groups 1, 2 and 3, respectively. In group 1, 70% of patients had low, 23.3% had moderate, and 6.6% had high physical activity levels. In group 2, 46.6% of patients had low, 36.6% had moderate, and 16.6% had high physical activity levels; in group 3, 23.3% had low, 53.4% had moderate, and 23.3% had high physical activity levels. There was a statistically significant difference in physical activity levels among the three groups and between group 1 and group 3 (<em>p</em> <!-->&lt;<!--> <!-->0.05), but no statistically significant difference was revealed in the remaining paired comparisons (<em>p</em> <!-->&gt;<!--> <!-->0.05). TSK score was positively and weakly correlated with VAS-pain (<em>p</em>:0.032, <em>r</em>:0.392) and rFIQ scores (<em>p</em>:0.025, <em>r</em>:0.408) in group 1, positively and strongly correlated with BDI scores (<em>p</em>:0.002, <em>r</em>:0.547) in group 1, and negatively and weakly correlated with physical activity levels (<em>p</em>:0.039, <em>r</em>: −0.378) in group 2.</div></div><div><h3>Conclusions</h3><div>The patients with group 1 and group 2 had higher levels of kinesiophobia, pain intensity, fatigue and a lower physical activity level than group 3.</div></div>","PeriodicalId":47115,"journal":{"name":"Reumatologia Clinica","volume":"21 4","pages":"Article 501849"},"PeriodicalIF":1.2,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143936690","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Sarcoidosis inducida por capecitabina en una paciente oncológica: presentación clínica con artritis","authors":"Yedra Usón-Rodríguez ,&nbsp;Fátima Mocha-Campillo ,&nbsp;Maialen Guerrero-Gómez ,&nbsp;Juan Lao-Romera ,&nbsp;Marina Soledad Moreno-García","doi":"10.1016/j.reuma.2025.501870","DOIUrl":"10.1016/j.reuma.2025.501870","url":null,"abstract":"<div><div>Sarcoidosis is a multisystemic granulomatous disease of uncertain etiology. Several drugs have been linked to the development of sarcoidosis or systemic granulomatous reactions indistinguishable from this disease. We present the clinical case of a patient diagnosed with breast cancer and undergoing treatment with capecitabine who, after developing systemic and musculoskeletal symptoms, was ultimately diagnosed with capecitabine-induced sarcoidosis.</div></div>","PeriodicalId":47115,"journal":{"name":"Reumatologia Clinica","volume":"21 4","pages":"Article 501870"},"PeriodicalIF":1.2,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143936694","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Mean corpuscular volume and red cell distribution width as predictors of methotrexate response in RA patients","authors":"Benitez Cristian Alejandro ,&nbsp;Gomez Ramiro Adrián ,&nbsp;Peón Claudia ,&nbsp;Alfaro María Agustina ,&nbsp;Federico Andrea ,&nbsp;Klimovsky Ezequiel ,&nbsp;Gamba María Julieta","doi":"10.1016/j.reuma.2025.501851","DOIUrl":"10.1016/j.reuma.2025.501851","url":null,"abstract":"&lt;div&gt;&lt;h3&gt;Objective&lt;/h3&gt;&lt;div&gt;To correlate ΔRDW and ΔVCM (baseline and week 12) with the number of patients achieving remission or low disease activity by CDAI at week 24 after initiating MTX.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Materials and methods&lt;/h3&gt;&lt;div&gt;Retro-prospective, analytical, and observational study in consecutive adult patients diagnosed with RA (ACR/EULAR 2010). Demographic data, clinical characteristics, personal history, initiated treatments, and VCM (fL) and RDW (%) at weeks 0, 4, 12, and 24 were evaluated. Safety data was recorded. Statistical analysis: descriptive analysis, Chi&lt;sup&gt;2&lt;/sup&gt; test or Fisher's exact test; Student's &lt;em&gt;T&lt;/em&gt;-test or Mann–Whitney; and ANOVA or Kruskal–Wallis. Lineal and/or multiple logistic regression.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Results&lt;/h3&gt;&lt;div&gt;139 patients were included, of whom 109 completed the study requirements. 83.5% were women, median age (m) 50 years (IQR 39–60), with a median disease duration of 12 months (IQR 0–78). In the per-protocol analysis of 109 patients, the m ΔRDW between baseline and week 12 was 0.8 (IQR 0–2.4), and the m ΔVCM was 2.0 (IQR 0.1–4.4). No correlation was found between ΔRDW and CDAI at week 24 (Rho&lt;!--&gt; &lt;!--&gt;=&lt;!--&gt; &lt;!--&gt;−0.08; &lt;em&gt;p&lt;/em&gt; &lt;!--&gt;=&lt;!--&gt; &lt;!--&gt;0.416), but a statistically significant correlation was found between ΔVCM and CDAI at week 24 (Rho&lt;!--&gt; &lt;!--&gt;=&lt;!--&gt; &lt;!--&gt;−0.190; &lt;em&gt;p&lt;/em&gt; &lt;!--&gt;=&lt;!--&gt; &lt;!--&gt;0.048).&lt;/div&gt;&lt;div&gt;Results were analyzed by intention to treat for 139 patients. Between baseline and week 12, a m ΔRDW of 0.8 (IQR 0–2.4) and a m ΔVCM of 2.2 (IQR 0.2–4.5) were recorded. No correlation was found between ΔRDW and CDAI at week 24 (Rho&lt;!--&gt; &lt;!--&gt;=&lt;!--&gt; &lt;!--&gt;−0.073; &lt;em&gt;p&lt;/em&gt; &lt;!--&gt;=&lt;!--&gt; &lt;!--&gt;0.433), but a statistically significant correlation was found between ΔVCM and CDAI at week 24 (Rho&lt;!--&gt; &lt;!--&gt;=&lt;!--&gt; &lt;!--&gt;−0.217; &lt;em&gt;p&lt;/em&gt; &lt;!--&gt;=&lt;!--&gt; &lt;!--&gt;0.018). 64.2%, 39.4%, and 15.6% of patients achieved CDAI 50/70/85 responses at week 12, respectively, with no significant changes at week 24. Univariate and multivariate analysis identified that the only factor significantly associated with achieving CDAI 50 at week 24 was achieving such a response at week 12 (&lt;em&gt;p&lt;/em&gt; &lt;!--&gt;=&lt;!--&gt; &lt;!--&gt;0.001).&lt;/div&gt;&lt;div&gt;Safety evaluation showed that 68 patients (48.9%) experienced adverse events, with 20 events (14.4%) related to MTX. Only 5 (3.6%) were considered serious adverse events, all of them unrelated to treatment.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Conclusions&lt;/h3&gt;&lt;div&gt;This study revealed that an increase in red cell distribution width (RDW) and mean corpuscular volume (VCM) was associated with the initiation of MTX treatment. However, only a significant correlation was found between the change in VCM and RA activity measured by CDAI at week 24. Although ΔRDW did not show a significant association with RA activity, ΔVCM negatively correlated with CDAI at week 24. Additionally, a significant percentage of patients achieved a positive response at week 12, but there were no significant changes at we","PeriodicalId":47115,"journal":{"name":"Reumatologia Clinica","volume":"21 4","pages":"Article 501851"},"PeriodicalIF":1.2,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143936688","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Association of electrocardiographic altered P wave dispersion and vascular endothelial growth factor in rheumatoid arthritis","authors":"Osmar Antonio Centurión ,&nbsp;Paloma de Abreu ,&nbsp;Gabriela Avila-Pedretti ,&nbsp;Sonia R. Cabrera ,&nbsp;María T. Martínez de Filártiga ,&nbsp;Astrid Paats ,&nbsp;Judith M. Torales ,&nbsp;Christian O. Chávez ,&nbsp;Carmen R. Montiel ,&nbsp;Laura B. García ,&nbsp;Karina E. Scavenius ,&nbsp;Rocío del Pilar Falcón ,&nbsp;Jose C. Candia ,&nbsp;Alfredo J. Meza ,&nbsp;Isabel Acosta-Colmán","doi":"10.1016/j.reuma.2025.501856","DOIUrl":"10.1016/j.reuma.2025.501856","url":null,"abstract":"<div><h3>Objectives</h3><div>Serum vascular endothelial growth factor (VEGF) levels correlate with structural alterations in Rheumatoid Arthritis (RA). Since P wave dispersion (PWD) is associated with atrial ischemic-related fibrotic changes, it was conceived that there may be a correlation between altered PWD and increased VEGF levels in RA.</div></div><div><h3>Methods</h3><div>In this prospective observational study, we evaluated patients with RA, and compared them to control subjects. PWD was considered as the difference between the maximum and minimum duration of the P wave. An altered PWD was considered one that had dispersion<!--> <!-->≥<!--> <!-->38<!--> <!-->ms. Measurements of VEGF serum levels were performed using enzyme-ligand, immunosorbent measurement ELISA kits.</div></div><div><h3>Results</h3><div>A total of 99 patients with RA, and 48 control subjects were evaluated. The PWD was 25.3<!--> <!-->±<!--> <!-->4.9<!--> <!-->ms in the control group vs. 57<!--> <!-->±<!--> <!-->14.9<!--> <!-->ms (<em>p</em> <!-->&lt;<!--> <!-->0.0001) in the RA group. No patient in the control group had altered PWD, while 94 (95%) patients in the RA group presented it (<em>p</em> <!-->&lt;<!--> <!-->0.0001). The value of VEGF in the control group was 15.2<!--> <!-->±<!--> <!-->15.1<!--> <!-->pg/ml vs 51.1<!--> <!-->±<!--> <!-->55.5<!--> <!-->pg/ml (<em>p</em> <!-->&lt;<!--> <!-->0.001) in RA. The value of VEGF in RA without altered PWD was 20<!--> <!-->±<!--> <!-->12<!--> <!-->pg/ml vs 56<!--> <!-->±<!--> <!-->57<!--> <!-->pg/ml in RA with altered PWD (<em>p</em> <!-->&lt;<!--> <!-->0.02). An elevated VEGF value had a specificity of 80%, and a positive predictive accuracy of 95% in predicting altered PWD in RA.</div></div><div><h3>Conclusions</h3><div>This study establishes for the first time that RA patients who possess significantly higher serum levels of VEGF have an altered PWD. The presence of an elevated VEGF serum value has a high specificity, and high positive predictive accuracy of the existence of altered PWD in RA.</div></div>","PeriodicalId":47115,"journal":{"name":"Reumatologia Clinica","volume":"21 4","pages":"Article 501856"},"PeriodicalIF":1.2,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143936689","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Síntomas neurológicos centrales como primera manifestación en la enfermedad de Sjögren","authors":"Dianela Gasca Saldaña ,&nbsp;Wallace Rafael Arturo Muñoz Castañeda ,&nbsp;Antonio Gonzalez Pineda ,&nbsp;Karen Burgueño Aguilar ,&nbsp;Andrés Vega Rosas","doi":"10.1016/j.reuma.2025.501846","DOIUrl":"10.1016/j.reuma.2025.501846","url":null,"abstract":"<div><div>Sjögren's disease it's a heterogeneous and complex rheumatological disease, can present central neurological manifestations, with a prevalence that varies between 1-5% according to the international literature. We report a series of three cases; we present a patient who debuted with epileptic seizures, one with catatonic syndrome and a last one with optic neuritis. Knowing the various presentations of the central neurological manifestations allows us to broaden the diagnostic suspicion from the beginning, providing timely treatment.</div></div>","PeriodicalId":47115,"journal":{"name":"Reumatologia Clinica","volume":"21 4","pages":"Article 501846"},"PeriodicalIF":1.2,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143936693","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Uso de anifrolumab en un paciente con síndrome de Rowell crónico multirrefractario","authors":"Carlota Navarro-Joven ,&nbsp;María Alonso de Francisco ,&nbsp;Margarita Pich-Aguilera Blasco ,&nbsp;Rita María Cabeza Martínez ,&nbsp;José Luis Andreu Sánchez ,&nbsp;Hildegarda Godoy-Tundidor","doi":"10.1016/j.reuma.2025.501845","DOIUrl":"10.1016/j.reuma.2025.501845","url":null,"abstract":"<div><div>Rowell's syndrome is an unusual form of subacute cutaneous lupus. We present the case of a male patient with chronic Rowell's syndrome, who exhibits a remarkable response to anifrolumab.</div></div>","PeriodicalId":47115,"journal":{"name":"Reumatologia Clinica","volume":"21 4","pages":"Article 501845"},"PeriodicalIF":1.2,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143936692","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Evaluación de los niveles séricos de IgG4 como herramienta de cribado de la enfermedad relacionada con IgG4: datos procedentes de un estudio retrospectivo","authors":"Pablo Martínez Calabuig ,&nbsp;Jorge Juan Fragío Gil ,&nbsp;Roxana González Mazarío ,&nbsp;Laura Salvador Maicas ,&nbsp;Mireia Lucía Sanmartín Martínez ,&nbsp;Antonio Sierra Rivera ,&nbsp;Laura Abenza Barberá ,&nbsp;María Cristina Sabater Abad ,&nbsp;Francesc Puchades Gimeno ,&nbsp;Inmaculada Castelló Miralles ,&nbsp;Amalia Rueda Cid ,&nbsp;Cristina Campos Fernández ,&nbsp;en representación del Grupo de trabajo de Enfermedad Relacionada con IgG4 del HGUV","doi":"10.1016/j.reuma.2025.501852","DOIUrl":"10.1016/j.reuma.2025.501852","url":null,"abstract":"<div><h3>Background and objective</h3><div>IgG4-related disease (IgG4-RD) is a systemic, immune-mediated, fibro-inflammatory condition with an uncertain etiology and pathophysiology that can affect multiple organs, presenting common clinical, radiological, and serological features. Although the disease is associated with IgG4, serum levels are not elevated in all patients and have also been described in other diseases. The aim of this study is to evaluate the clinical utility of elevated serum IgG4 as a screening marker in the suspicion of IgG4-RD.</div></div><div><h3>Materials and methods</h3><div>A retrospective single-center study was conducted, analyzing serological IgG4 test requests from electronic medical records of patients ordered by various hospital departments from January 2010 to June 2023. Only those with elevated IgG4 levels were included in the analysis. Additionally, demographic data and final diagnoses, including those with IgG4-RD, were collected.</div></div><div><h3>Results</h3><div>A total of 2,288 test requests were reviewed, of which 247 showed elevated IgG4 levels (181 after excluding duplicates). Among the patients with elevated IgG4, only 11 met the criteria for IgG4-RD based on the 2011 Umehara-Okazaki classification and its 2020 update. However, only 6 patients (3.31%) met the more recent 2019 ACR/EULAR classification criteria for IgG4-RD. In the remaining patients with elevated IgG4, the most common diagnoses were respiratory diseases, such as COPD and asthma, followed by systemic autoimmune diseases, primarily SLE, RA, and EGPA. Elevated IgG4 levels were also observed in malignant neoplasms, predominantly lung and hematologic cancers.</div></div><div><h3>Conclusions</h3><div>Our study highlights that elevated IgG4 levels are not exclusive to IgG4-RD and can also be observed in various respiratory diseases (e.g., COPD), autoimmune diseases (e.g., SLE and RA), and neoplasms (e.g., lung cancer).</div></div>","PeriodicalId":47115,"journal":{"name":"Reumatologia Clinica","volume":"21 4","pages":"Article 501852"},"PeriodicalIF":1.2,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143936780","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}